Edwards Lifesciences Corp (EW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Edwards Lifesciences Corp (EW) has a cash flow conversion efficiency ratio of 0.004x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($43.80 Million) by net assets ($10.33 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check EW capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Edwards Lifesciences Corp - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Edwards Lifesciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Edwards Lifesciences Corp (EW) shareholders funds for net asset value and shareholders' equity analysis.
Edwards Lifesciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Edwards Lifesciences Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Banco Santander Brasil SA ADR
NYSE:BSBR
|
0.309x |
|
Mercedes-Benz Group AG
F:MBG
|
0.029x |
|
Montage Technology Co Ltd
SHG:688008
|
0.026x |
|
UCB SA
BR:UCB
|
0.140x |
|
Polski Koncern Naftowy ORLEN SA
WAR:PKN
|
0.089x |
|
Westinghouse Air Brake Technologies Corp
NYSE:WAB
|
0.018x |
|
STMicroelectronics N.V
F:SGMR
|
0.029x |
|
DnB ASA
OL:DNB
|
0.400x |
Annual Cash Flow Conversion Efficiency for Edwards Lifesciences Corp (1999–2025)
The table below shows the annual cash flow conversion efficiency of Edwards Lifesciences Corp from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see Edwards Lifesciences Corp market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.34 Billion | $1.60 Billion | 0.154x | +186.34% |
| 2024-12-31 | $10.06 Billion | $542.30 Million | 0.054x | -59.58% |
| 2023-12-31 | $6.72 Billion | $895.80 Million | 0.133x | -36.45% |
| 2022-12-31 | $5.81 Billion | $1.22 Billion | 0.210x | -29.32% |
| 2021-12-31 | $5.84 Billion | $1.73 Billion | 0.297x | +28.77% |
| 2020-12-31 | $4.57 Billion | $1.05 Billion | 0.230x | -18.93% |
| 2019-12-31 | $4.15 Billion | $1.18 Billion | 0.284x | -3.66% |
| 2018-12-31 | $3.14 Billion | $926.80 Million | 0.295x | -11.68% |
| 2017-12-31 | $2.99 Billion | $1.00 Billion | 0.334x | +24.24% |
| 2016-12-31 | $2.62 Billion | $704.40 Million | 0.269x | +22.47% |
| 2015-12-31 | $2.50 Billion | $549.70 Million | 0.220x | -52.92% |
| 2014-12-31 | $2.19 Billion | $1.02 Billion | 0.467x | +53.88% |
| 2013-12-31 | $1.56 Billion | $472.70 Million | 0.303x | +19.98% |
| 2012-12-31 | $1.48 Billion | $373.80 Million | 0.253x | +7.49% |
| 2011-12-31 | $1.34 Billion | $314.50 Million | 0.235x | +22.32% |
| 2010-12-31 | $1.31 Billion | $251.40 Million | 0.192x | +34.61% |
| 2009-12-31 | $1.16 Billion | $165.30 Million | 0.143x | -18.11% |
| 2008-12-31 | $878.80 Million | $153.20 Million | 0.174x | -30.75% |
| 2007-12-31 | $835.00 Million | $210.20 Million | 0.252x | -18.26% |
| 2006-12-31 | $749.40 Million | $230.80 Million | 0.308x | +55.34% |
| 2005-12-31 | $690.00 Million | $136.80 Million | 0.198x | -31.05% |
| 2004-12-31 | $628.10 Million | $180.60 Million | 0.288x | +49.32% |
| 2003-12-31 | $635.10 Million | $122.30 Million | 0.193x | -13.87% |
| 2002-12-31 | $539.40 Million | $120.60 Million | 0.224x | +1.61% |
| 2001-12-31 | $459.00 Million | $101.00 Million | 0.220x | -29.33% |
| 2000-12-31 | $440.00 Million | $137.00 Million | 0.311x | +116.54% |
| 1999-12-31 | $1.22 Billion | $176.00 Million | 0.144x | -- |
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to t… Read more